Derma Sciences Business Agreement Attributes to Patient Lifestyle Needs

       Derma Sciences, Inc. (Princeton, NJ) announces that the company has obtained a licensing agreement with C-Boot LTD, a medical biosystems company based in Israel.
       The agreement was established for the marketing, sales, and distribution rights of C-Boot’s patented advanced therapeutic devices for the treatment of chronic venous insufficiency (CVI), venous ulcers, lymphedema, deep vein thrombosis (DVT) prevention, and other conditions that require compression therapy.
       Derma Sciences will market C-Boot’s products under the MOBILITY 1™ brand. The products are the world’s first and only intermittent pneumatic compression (IPC) therapy devices for all of these indications that allow for full patient mobility. Several US patents cover the technologies inherent within the device.
       Until now, IPC therapy has required that the patient remain immobile while connected to a large pneumatic compressor. Ambulatory treatments have been limited to compression wraps and stockings, which have low compliance, are painful, and do not provide optimal therapy.
       This system can be activated either by kinetic energy created from the patient walking (fully utilizing the patient’s calf muscle pump) or, by a small, portable compressor.
       Patients will now be able to maintain their regular lifestyle by taking therapy wherever they go. The products are designed to be easy to wear and use.
       Visit http://www.dermasciences.com or call 609-514-4744 for more information.

Hill-Rom and Tempur-Pedic Join Forces to Globally Improve Patient Sleep Conditions